Skip to main content
SpringerLink
Log in

Lorcaserin: no increased risk of cardiovascular events

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients–Thrombolysis in Myocardial Infarction 61

References

  1. Bohula EA, et al. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. New England Journal of Medicine : 26 Aug 2018. Available from: URL: http://dx.doi.org/10.1056/NEJMoa1808721.

  2. Ingelfinger JR, et al. Lorcaserin - Elixir or Liability? New England Journal of Medicine : 26 Aug 2018. Available from: URL: http://dx.doi.org/10.1056/NEJMe1810855.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lorcaserin: no increased risk of cardiovascular events. Reactions Weekly 1718, 6 (2018). https://doi.org/10.1007/s40278-018-51350-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-51350-y

Search

Navigation